Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized insulin sensitivity Tel Aviv,... | January 7, 2023

Related Keywords

Israel ,Boston ,Massachusetts ,United States ,Jerusalem ,Israel General ,Canada ,Hebrew University ,Yerushalayim ,Tel Aviv ,Frankfurt ,Brandenburg ,Germany ,Canadian ,Joseph Tam ,Saja Baraghithy ,Adi Zuloff Shani ,Morgan Stanley ,Hebrew University Institute For Drug Research ,Nasdaq ,Novartis ,Hebrew University Of Jerusalem ,Canadian Securities Exchange ,Intel ,Clearmind Medicine Inc ,World Health Organization ,Boston Scientific ,Frankfurt Stock Exchange ,Metabolism Laboratory ,Hebrew University Of Jerusalem Is Israel ,Johnson ,Novo Nordisk ,Chief Executive Officer ,Associate Professor ,Drug Research ,Nobel Prizes ,Fields Medal ,Clearmind Medicine Inc Stock Exchange ,News ,Information ,Press Release ,N ,Series ,F ,Drug ,Candidate ,Deai ,Ignificantly ,Educed ,Body ,Mproved ,Patty ,Liver ,End ,Normalized ,Insulin ,Sensitivity ,El Cmnd Ca1850532047 ,